جستجوی مقالات مرتبط با کلیدواژه « prednisone » در نشریات گروه « پزشکی »

Nephrotic syndrome is a clinical manifestation of glomerular  disease characterized by severe or nephrotic-range proteinuria >3.5 g/24 hours. The treatment of nephrotic syndrome using corticosteroid especially prednisone, belongs to a class of glucocorticoid. Glucocorticoids are proven  to be  able to inhibit growth through several mechanisms.  The objective of this study  was  to  analyze  the  characteristic  of  height  in  childhood  nephrotic syndrome  and  analyze  the  correlation  between corticosteroid therapy and height in childhood nephrotic syndrome.

 This systematic review was conducted using the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA)  guideline.  The  literature  search  was  conducted  in  November  2020  in  four  databases:  PubMed,  Science  Direct, Scopus, and DOAJ. Quality assessment was carried out using a quality assessment tool for quantitative studies from EPHPP.

Six studies met the inclusion criteria for final analysis.  The mean final height z-scores were -0.66 ± 3.04. The height z-scores of Steroid-Dependent Nephrotic Syndrome (SDNS) (-0.33 ± 0.87) and Steroid-Resistant Nephrotic Syndrome (SRNS) (-0.97  ±  1.34)  patients  were  lower  than  Steroid-Sensitive  Nephrotic  Syndrome  (SSNS)  (-0.20  ±  3.14)  patients.  The height  zscores of nephrotic syndrome children were significantly lower than a normal population.  Five studies suggested that there is a correlation  between  corticosteroid  therapy  and  height  on  childhood  nephrotic syndrome  and  one  study  did  not  find  a correlation between them.

 According  to  findings,  there  is  a  negative  correlation  between  corticosteroid  therapy  and  height  in childhood nephrotic syndrome. Nephrotic syndrome children had significantly lower height z-scores than a normal population. The SDNS and  SRNS  patients  are  more  susceptible  to  have  a  lower  height  than  SNSS  patients  as  they  have  a  higher  cumulative corticosteroid dose.

The aim of this study was to evaluate and compare the therapeutic efficacy of subcutaneous enoxaparin versus oral prednisone (as a standard treatment) in patients with disseminated lichen planus.

In this parallel randomized clinical trial study, overall 48 patients completed the study. 25 patients were treated with subcutaneous enoxaparin 5 mg weekly and 23 patients with 0.5 mg/kg prednisone orally daily until complete remission or a maximum of 8 weeks. The results of itching severity, extent of active lesions and drug side effects were compared. In remission, patients were followed for 6 months for recurrent lesions.

In enoxaparin group, 8 patients (32%) had complete remission and 10 patients (40%) had partial improvement. In the oral prednisone group, 16 patients (69.6%) had complete remission and 6 patients (26.1%) had partial improvement (P = 0.005). Average size of active lesions in both groups decreased significantly after treatment, but analysis of covariance showed that the mean lesion size after treatment in the oral prednisone group was significantly lower than the enoxaparin group (P = 0.005). The relapse rate from improved patients in the enoxaparin group was 6 (33%) and in oral prednisone group was 9 (40.9%, P = 0.083). In the enoxaparin group no serious complications was seen. But 22% in the oral prednisone group show side effect, the most common complications were dyspepsia.

Low dose enoxaparin on lichen Planus have therapeutic effect and is important for the least side effects but not as much as oral prednisone. But it could be accepted as an alternative treatment.

Steroids are commonly used in the treatment of cervical radiculopathy (CR), but there is limited information in this regard. We evaluated the efficacy of oral prednisone in the treatment of CR. This randomized, double-blinded, placebo-controlled trial was conducted on adult patients with neck/shoulder pain for at least 1 month with no alarm symptoms/sings of malignancy, infection, or severe myelopathy, and no contraindication for corticosteroid use. Patients were allocated to receive prednisolone 50 mg/day for 5 days that was tapered within the following 5 days, or placebo. All patients also received acetaminophen 325 mg three times a day and ranitidine 150 mg two times a day. Neck disability index (NDI) and the verbal rating scale (VRS) were used to evaluate the outcomes. A total of 59 patients (31 female, mean ± SD age = 46.2±9.0 years) completed the study. A significant decrease was observed regarding the NDI and VAS scores from baseline to the end of study in both groups (P < 0.001). However, for both the NDI (35.7±21.4 vs. 12.9±10.2) and VRS (4.4±2.7 vs. 1.6±1.2), the amount of decrease was greater in the prednisone compared with the placebo group (P < 0.001). Based on the clinically important change in NDI, pain was improved in 75.8% (22/29) of the prednisolone and 30% (9/30) of the placebo group (P < 0.001). A short course of oral steroid therapy with prednisolone is highly effective in reducing pain in patients referring with uncomplicated CR. Further studies are warranted on dosing, duration, and long-term efficacy and safety of oral steroid therapy, compared with injection approach.